Middle East & Africa Cancer Vaccines Market
Published On: Oct 2020
Published On: Oct 2020
Cancer Vaccines Market for Dendritic Cells Cancer VaccinesSegment to Grow at Fastest CAGR during Forecast Period
According to our new market research study on “Cancer Vaccines Market to 2027 – Middle East & Africa Analysis and Forecast – by Technology, Type, Indication, and End Use,”the market is expected to reach US$ 779.60 million by 2027; it is expected to grow at a CAGR of 15.5% during the forecast period. The report highlights trends prevailing in the Middle East & AfricaCancer Vaccines Market and the drivers and restraints pertaining to the market growth.
Based on technology, the Cancer Vaccines market is segmented into in dendritic cells cancer vaccines, recombinant cancer vaccines, antigen cancer vaccines, whole cell cancer vaccines, viral vector cancer vaccines. The in recombinant cancer vaccines segment held the largest share of the market in 2019. Moreover, recombinant cancer vaccines is estimated grow at the highest CAGR in the market during the forecast period.
Market growth in Middle East & Africa Cancer Vaccines is mainly due to factors such as increasing prevalence of cancer and rising government initiatives to prevent cancer. However, challenges such as costly costs in the cancer vaccine industry restrict the growth of the market.
AstraZeneca, GlaxoSmithKline plc., Aduro Biotech Inc, Pfizer Inc., Sanofi, Bristol-Myers Squibb, Moderna, Inc., OncBioMune Pharmaceuticals Inc., MaxiVAX, Nouscomare among the leading companies operating in the Cancer Vaccines Market.
Middle East & AfricaCancer Vaccines market, By Country, 2019 (%)
The report segments Middle East & AfricaCancer Vaccinesmarket as follows:
ByTechnology
By Country
E 1803, Panchshil Towers, Vagholi, Haveli, Pune- 412207, Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
